Prosecution Insights
Last updated: April 19, 2026

Goldfinch Bio Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17766492 BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE BARSKY, JARED 1628 Non-Final OA Apr 04, 2022
17360303 PYRIDAZINONES AND METHODS OF USE THEREOF SHOWALTER, ALEXANDER KEITH 1629 Final Rejection Jun 28, 2021
16636606 BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF HASTINGS, ALISON AZAR 1627 Final Rejection Feb 04, 2020

Managing Goldfinch Bio Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month